Crixivan is a drug owned by Merck Sharp And Dohme Corp. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 10, 2021. Details of Crixivan's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6689761 | Combination therapy for HIV infection |
Feb, 2021
(3 years ago) |
Expired
|
| US6645961 | Dry granulation formulation for an HIV protease inhibitor |
Mar, 2018
(6 years ago) |
Expired
|
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Crixivan and ongoing litigations to help you estimate the early arrival of Crixivan generic.
Crixivan's Litigations
Crixivan been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Mar 22, 2001, against patent number US6689761. The petitioner , challenged the validity of this patent, with CHODAKEWITZ et al as the respondent. Click below to track the latest information on how companies are challenging Crixivan's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6645961 | June, 2001 |
Decision
(27 Mar, 2002) | LUI et al | |
| US6689761 | March, 2001 |
Decision
(25 May, 2001) | CHODAKEWITZ et al | |
US patents provide insights into the exclusivity only within the United States, but Crixivan is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Crixivan's family patents as well as insights into ongoing legal events on those patents.
Crixivan's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Crixivan's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 10, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Crixivan Generics:
There are no approved generic versions for Crixivan as of now.
About Crixivan
Crixivan is a drug owned by Merck Sharp And Dohme Corp. It is used for managing HIV infection when used in combination with other antiretroviral agents. Crixivan uses Indinavir Sulfate as an active ingredient. Crixivan was launched by Merck Sharp Dohme in 2000.
Approval Date:
Crixivan was approved by FDA for market use on 19 April, 2000.
Active Ingredient:
Crixivan uses Indinavir Sulfate as the active ingredient. Check out other Drugs and Companies using Indinavir Sulfate ingredient
Treatment:
Crixivan is used for managing HIV infection when used in combination with other antiretroviral agents.
Dosage:
Crixivan is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 200MG BASE | CAPSULE | Discontinued | ORAL |
| EQ 333MG BASE | CAPSULE | Discontinued | ORAL |
| EQ 100MG BASE | CAPSULE | Discontinued | ORAL |
| EQ 400MG BASE | CAPSULE | Discontinued | ORAL |